

Shield Therapeutics plc
("Shield" or the "Company")

Director / PDMR Shareholding

London, UK, 15 August 2019, Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces that James Karis, Chairman of the Company, has acquired 75,000 Ordinary Shares in the Company on 13 August 2019 for consideration of £1.78 per Ordinary Share. Following the transaction, Mr Karis holds 161,667 shares, representing 0.001% of the Company's issued share capital.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	James Karis
2	Reason for the notification	
a)	Position/status	Chairman
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Acquisition of Ordinary Shares
c)	Price(s) and volume(s)	£1.78 per Ordinary Share Volumes: 75,000
d)	Aggregated information -Aggregated volume -Price	 75,000 £133,500
e)	Date of the transaction	13 August 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

For further information please contact:

Shield Therapeutics plc

Carl Sterritt, Chief Executive Officer
Tim Watts, Chief Financial Officer

www.shieldtherapeutics.com

+44 (0)20 7186 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash /Matt Radley/ Alice
Lane

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Paul McManus / Lianne Cawthorne

+44 (0)20 7933 8780 or shield@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®/Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru®/Accrufer® is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected. For more information please visit www.shieldtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Feraccru®/Accrufer®. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHKELBFKVFFBBQ